Modest growth forecast for global Crohn’s disease market

4 February 2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2 billion in 2012 to $4.2 billion by 2022, at a compound annual growth rate (CAGR) of 2.8%, according to a new report from research and consulting firm GlobalData.

The company’s latest report states that out of the 10 major markets (10MM: the USA, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India), the USA will continue to hold the largest CD market share by 2022, with 68%, followed by Canada and Japan with 8% and 7%, respectively.

Entyvio and Stelara likely market drivers

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK